Quantcast

Cosmetic Dentist in Buffalo, NY, Announces New Product for Lip Augmentation

May 27, 2012

Dr Nicholas Rodo, a cosmetic dentist who serves the Buffalo, NY area, announced that he will be using the new FDA approved Restylane on his Lip Augmentation patients.

Buffalo, NY (PRWEB) May 26, 2012

The new product, Restylane, is a crystal clear injectable gel composed of hyaluronic acid, a natural substance that already exists in the body. Restylane is non-animal based and free from animal protein, and makes normal allergy pretesting no longer necessary. The product is a dermal filler that can be used to restore lost volume in the lips & improve esthetic deficiencies….and essentially take years off a patient’s appearance.

When asked to comment on the product Dr Rodo said, “I’ve had comments like, ℠Wow! The after pictures look 20 years younger!´”

With this class of dermal filler it is now possible to also correct/augment folds noticeable alongside the nose or corners of the mouth. It’s safe (FDA Approved), and an excellent reversible corrective enhancement service without any surgery or downtime.

This product is mostly used for lip enhancement. After being numbed first with a painless local anesthetic, the Restylane is injected into your lips with an ultrafine needle to plump the skin & smooth away wrinkles and folds. It can also be injected into the skin to minimize the lines from your nose to the corners of your mouth (nasolabial folds).

The effects generally last at least six months and gradually disappear from the body. If you are treated again at 4 ½ or 9 months after your first treatment, Restylane can last up to 18 months in the nasolabial folds. In the lips Restylane generally lasts six months.

For information on this product & the treatments it´s used for:

Contact: Dr Nicholas Rodo

Company Name: Dr Nicholas Rodo

Telephone Number: 716-675-2900

Email Address: nicholasrodo(at)hotmail(dot)com

Web site address: http://www.wegotsmiles.com/

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/5/prweb9543346.htm


Source: prweb



comments powered by Disqus